亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation

达帕格列嗪 医学 主动脉瓣 内科学 心脏病学 糖尿病 2型糖尿病 内分泌学
作者
Sergio Raposeiras‐Roubín,Ignacio Jesus Amat-Santos,Xavier Rosselló,Rocío González-Ferreiro,Inmaculada González Bermúdez,Diego López‐Otero,Luis Nombela-Franco y,Livia Luciana Gheorghe,Jose L. Diez,Carlos Baladrón,José Antonio Baz,Antonio J. Muñoz-García,Victòria Vilalta,Soledad Ojeda,José M. de la Torre Hernández,Juan Gabriel Córdoba Soriano,Ander Regueiro,Pascual Bordes Siscar,Jorge Salgado Fernández,Bruno García del Blanco
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:392 (14): 1396-1405 被引量:161
标识
DOI:10.1056/nejmoa2500366
摘要

BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of heart-failure admission among high-risk patients. However, most patients with valvular heart disease, including those undergoing transcatheter aortic-valve implantation (TAVI), have been excluded from randomized trials. METHODS: We conducted this randomized, controlled trial in Spain to evaluate the efficacy of dapagliflozin (at a dose of 10 mg once daily) as compared with standard care alone in patients with aortic stenosis who were undergoing TAVI. All the patients had a history of heart failure plus at least one of the following: renal insufficiency, diabetes, or left ventricular systolic dysfunction. The primary outcome was a composite of death from any cause or worsening of heart failure, defined as hospitalization or an urgent visit, at 1 year of follow-up. RESULTS: A total of 620 patients were randomly assigned to receive dapagliflozin and 637 to receive standard care alone after TAVI; after exclusions, a total of 1222 patients were included in the primary analysis. A primary-outcome event occurred in 91 patients (15.0%) in the dapagliflozin group and in 124 patients (20.1%) in the standard-care group (hazard ratio, 0.72; 95% confidence interval [CI], 0.55 to 0.95; P = 0.02). Death from any cause occurred in 47 patients (7.8%) in the dapagliflozin group and in 55 (8.9%) in the standard-care group (hazard ratio, 0.87; 95% CI, 0.59 to 1.28). Worsening of heart failure occurred in 9.4% and 14.4% of the patients, respectively (subhazard ratio, 0.63; 95% CI, 0.45 to 0.88). Genital infection and hypotension were significantly more common in the dapagliflozin group. CONCLUSIONS: Among older adults with aortic stenosis undergoing TAVI who were at high risk for heart-failure events, dapagliflozin resulted in a significantly lower incidence of death from any cause or worsening of heart failure than standard care alone. (Funded by Instituto de Salud Carlos III and others; ClinicalTrials.gov number, NCT04696185.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
北侨发布了新的文献求助10
1秒前
苼安子完成签到 ,获得积分10
43秒前
Ahui完成签到 ,获得积分10
44秒前
54秒前
北侨发布了新的文献求助10
1分钟前
1分钟前
Linden_bd完成签到 ,获得积分0
1分钟前
1分钟前
2分钟前
2分钟前
zumri发布了新的文献求助30
2分钟前
2分钟前
2分钟前
3分钟前
3分钟前
sugar发布了新的文献求助10
3分钟前
3分钟前
天天快乐的应助被sugar采纳,获得10
3分钟前
3分钟前
北侨发布了新的文献求助10
3分钟前
3分钟前
4分钟前
Jianing的应助被辛勤寻凝采纳,获得10
4分钟前
4分钟前
乐观的蜗牛完成签到 ,获得积分10
5分钟前
5分钟前
sugar发布了新的文献求助10
5分钟前
5分钟前
5分钟前
ding的应助被sugar采纳,获得10
5分钟前
5分钟前
aspect完成签到 ,获得积分10
6分钟前
6分钟前
乐正元正完成签到,获得积分10
6分钟前
Jomain完成签到,获得积分10
6分钟前
wanci的应助被Jomain采纳,获得10
6分钟前
搜集达人的应助被XXXXXX采纳,获得10
6分钟前
梵瑾妄完成签到 ,获得积分10
6分钟前
6分钟前
6分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195167
求助须知:如何正确求助?哪些是违规求助? 9580906
关于积分的说明 21872987
捐赠科研通 7795162
什么是DOI,文献DOI怎么找? 3437967
关于科研通互助平台的介绍 2561259
邀请新用户注册赠送积分活动 2484678